This Article Full Text Full Text (PDF) All Versions of this Article: 36/1/118    most recent 01.STR.0000149620.74770.2ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belayev, L. Articles by Bazan, N. G. Search for Related Content PubMed PubMed Citation Articles by Belayev, L. Articles by Bazan, N. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dietary Fats Related Collections Animal models of human disease Acute Cerebral Infarction Brain Circulation and Metabolism Pathology of Stroke Neuroprotectors

(Stroke. 2005;36:118.)
© 2005 American Heart Association, Inc.

Original Contributions

Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection

Ludmila Belayev, MD; Victor L. Marcheselli, PhD; Larissa Khoutorova, BS; Elena B. Rodriguez de Turco, PhD; Raul Busto, BS; Myron D. Ginsberg, MD Nicolas G. Bazan, MD, PhD

From the Cerebral Vascular Disease Research Center (L.B., L.K., R.B., M.D.G.), Department of Neurology, University of Miami School of Medicine, Miami, FL; and the Neuroscience Center of Excellence and Department of Ophthalmology (V.L.M., E.B.R.d.T., N.G.B.), Louisiana State University Health Sciences Center, New Orleans, La.

Correspondence to Dr Myron D. Ginsberg, Department of Neurology (D4–5), University of Miami School of Medicine, PO Box 016960, Miami, FL 33101. E-mail mdginsberg{at}stroke.med.miami.edu

Background and Purpose— High-dose human albumin therapy is strongly neuroprotective in models of brain ischemia and trauma and is currently being studied in a pilot-phase clinical stroke trial. Among its actions in ischemia, albumin induces the systemic mobilization of n-3 polyunsaturated fatty acids and may help to replenish polyunsaturated fatty acids lost from neural membranes.

Methods— We complexed 25% human albumin to docosahexaenoic acid (DHA; 22:6n-3) and compared its neuroprotective efficacy with that of native albumin in rats with 2-hour focal ischemia produced by intraluminal suture-occlusion of the middle cerebral artery.

Results— In animals treated with DHA–albumin, 0.63 g/kg, the improvement in neurobehavioral scores at 72 hours significantly exceeded that of other treatment groups, and the extent of histological protection (86% reduction in cortical infarction) was highly significant and tended to surpass the degree of cortical protection produced by native albumin at 1.25 g/kg (65%). DHA–albumin 0.63 g/kg, but not native albumin, also significantly reduced subcortical infarction and markedly diminished brain swelling. Lipidomic analysis of DHA–albumin-treated postischemic brains revealed a large accumulation of the neuroprotective DHA metabolite, 10,17S-docosatriene, in the ipsilateral hemisphere.

Conclusions— The high-grade neuroprotection afforded by the DHA–albumin complex at relatively low albumin doses is clinically advantageous in that it might reduce the likelihood of acute intravascular volume overload and congestive heart failure sometimes induced when patients with compromised cardiovascular function are treated with high-dose albumin.

Key Words: albumins • fatty acids • ischemia • neuroprotection • rats

This article has been cited by other articles:

				L. Belayev, L. Khoutorova, K. D. Atkins, and N. G. Bazan Robust Docosahexaenoic Acid-Mediated Neuroprotection in a Rat Model of Transient, Focal Cerebral Ischemia Stroke, September 1, 2009; 40(9): 3121 - 3126. [Abstract] [Full Text] [PDF]

				N. G. Bazan Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease J. Lipid Res., April 1, 2009; 50(Supplement): S400 - S405. [Abstract] [Full Text] [PDF]

				N. G. Bazan Homeostatic Regulation of Photoreceptor Cell Integrity: Significance of the Potent Mediator Neuroprotectin D1 Biosynthesized from Docosahexaenoic Acid The Proctor Lecture Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4866 - 4881. [Full Text] [PDF]

				W. L. Huang, V. R. King, O. E. Curran, S. C. Dyall, R. E. Ward, N. Lal, J. V. Priestley, and A. T. Michael-Titus A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury Brain, November 1, 2007; 130(11): 3004 - 3019. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg and M. D. Hill Response to Letter by Parkkinen et al Stroke, February 1, 2007; 38(2): 256 - 256. [Full Text] [PDF]

				C. N. Serhan, K. Gotlinger, S. Hong, Y. Lu, J. Siegelman, T. Baer, R. Yang, S. P. Colgan, and N. A. Petasis Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes J. Immunol., February 1, 2006; 176(3): 1848 - 1859. [Abstract] [Full Text] [PDF]